Structure-based discovery of anti-viral compounds for hepatitis B & C, human immunodeficiency, and dengue viruses

Current Bioinformatics

Volumn 7, Issue 2, 2012, Pages 187-211

  Velmurugan, Devadasan ^a   Selvi, Udhayasuriyan Malar ^a   Mythily, Udhayakumar ^a   Rao, Kutumba ^a   Rajarajeshwari, Ramaiah ^a   Sangeetha, ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Anti virals; DENV; HBV; HCV; Natural resources; Structure based drug design

Indexed keywords

LEAD COMPOUNDS; NATURAL RESOURCES; PROTEINS; VIRUSES;

ANTI-VIRALS; DENGUE VIRUS; DENV; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN LIVES; STRUCTURE BASED DRUG DESIGNS; STRUCTURE-BASED;

DISEASES;

ACRIDONE DERIVATIVE; ANTIVIRUS AGENT; BENZIMADAZOLE; CIRCULAR DNA; DEOXYCYTIDINE KINASE; DNA POLYMERASE; DOUBLE STRANDED DNA; GAG PROTEIN; HEAT SHOCK PROTEIN 90; HELICASE; HELIOXANTHIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTEGRASE; MALE B363 PROTEIN; MESSENGER RNA; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; RECOMBINANT PROTEIN; RIBONUCLEASE H; TRIPHENYLMETHANE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

AEGLE MARMELOS; AMINO TERMINAL SEQUENCE; ARTICLE; AZADIRACHTA INDICA; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CATALYTIC CORE DOMAIN; CODON; CRAB; CRYSTAL STRUCTURE; DENGUE VIRUS; DNA BINDING; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME STRUCTURE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LIFE CYCLE; MURRAYA KOENIGII; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; THALAMITA CRENATA; VIRUS GENOME; VIRUS REPLICATION;

AEGLE MARMELOS; AZADIRACHTA INDICA; DECAPODA (CRUSTACEA); DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRIDAE; HELIOPSIS HELIANTHOIDES SUBSP. SCABRA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MURRAYA KOENIGII; PISCES; TAIWANIA CRYPTOMERIOIDES;

EID: 84861165464     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489312800604462     Document Type: Article

References (65)

1. Holger S, Rolf H. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr Top Med Chem 2010; 10: 323-345.
2. Biswal BK, Cherney MM, Wang M, et al. Crystal structures of the RNA-dependent RNA polymerase Genotype 2a of Hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005; 280: 18202-18210.
3. Seegar C, Mason WS. Hepatitis B Virus Biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
4. Delius H, Gough NM, Cameron CH, Murray K. Structure of the Hepatitis B Virus genome. J Virol 1983; 47: 337-343.
5. Nassal M, Leifer I, Wingert I, Dallmeier K, Prinz S, Vorreiter J. A structural model for duck Hepatitis B virus core protein derived by Extensive Mutagenesis. J Virol 2007; 81: 13218-13229.
6. Bouchard MJ, Schneider RJ. The Enigmatic X gene of Hepatitis B Virus. J Virol 2004; 78: 12725-12734.
7. Cho HS, Ha NC, Kang LW, et al. Crystal structure of RNA Helicase from genotype 1b Hepatitis C Virus. J Biol chem 1998; 273:15045-15052.
8. Simmonds P. Genetic diversity and evolution of hepatitis C virus- 15 years on. J Gen virol 2004; 85: 3173-3188.
9. Frick DN. The Hepatitis C Virus NS3 Protein: A model RNA Helicase and potential drug target. Curr Issues Mol Biol 2007; 9: 1-20.
10. Frick DN. A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities. Methods Mol Biol 2010; 587: 223-233.
11. Lam AM, Keeny D, Frick DN. Two novel conserved motifs in the Hepatitis C Virus NS3 protein critical for helicase action. J Biol Chem 2003; 278(45): 44514-44524.
12. Briguglio I, Piras S, Corona P, Carta A. Inhibition of RNA Helicases of ssRNA+ Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families. Int J Med chem 2011: 1-22.
13. Francesco RD, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-960.
14. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Mol Biol 1999; 6: 937-943.
15. Lawn SD. AIDS in Africa: the impact of co-infections on the pathogenesis of HIV-1 infection. J Infect Dis 2004; 48:1-12.
16. Goldgur Y, Craigie R, Gerson H. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. J Med Chem 1999; 96:13040-13043.
17. Tomlinson SM, Malmstrom RD, Watowich SJ. New approaches to structure-based discovery of dengue protease inhibitors. Drug Targets Infect Disord 2009; 9: 327-343.
18. Brooks AJ, Johansson M, Criswell E, Jans DA, Vasudevan SG. The interdomain region of Dengue NS5 protein interacts with NS3 and Host Proteins. Dengue Bull 2002; 26: 155-1561.
19. Tambunan USF, Alamudi S. Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Bioinformation 2010; 5: 250-254.
20. Katzenmeier G. Inhibition of the NS2B-NS3 Protease - Towards a causative therapy for dengue virus diseases. Dengue Bull 2004; 28: 58-67.
21. Kee LY, Kiat TS, Wahab AH, Yusof R, Rahman NA. Nonsubstrate based inhibitors of dengue virus serine protease: A molecular docking approach to study binding interactions between protease and inhibitors. Asia Pac J Mol Biol Biotechnol 2007; 15: 53-59.
22. Salaemae W, Junaid M, Angsuthanasombat C, Katzenmeier G. Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3. J Biomed Sci 2010; 17: 1-8.
23. Xu T, Sampath A, Chao A, et al. Structure of the Dengue Virus Helicase/Nucleoside Triphosphatase Catalytic Domain at a Resolution of 2.4 Å. J Virol 2005; 79: 10278-10288.
24. Yap TL, Xu T, Chen YL, et al. Crystal Structure of the Dengue Virus RNA-Dependent RNA polymerase Catalytic Domain at 1.85 -Angstrom Resolution. J Virol 2007; 81: 4753-4765.
25. Johansson M, Brooks AJ, Jans DA, Vasudevan SG. A small region of the dengue virus-encoded RNA-dependent RNA Polymerase, NS5, confers interaction with both the nuclear transport receptor importin-β and the viral helicase, NS3. J Gen Virol 2001; 82: 735-745.
26. Luo D, Xu T, Watson RP, et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J 2008; 27: 3209-3219.
27. Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J. Crystal Structure of the NS3 Protease-Helicase from Dengue Virus. J Virol 2008; 82: 173-183.
28. Assenberg R, Mastrangelo E, Walter TS, et al. Crystal Structure of a novel conformational state of the Flavivirus NS3 protein: Implications for polyprotein processing and viral replication. J Virol 2009; 83: 12895-12806.
29. Toy G, Austin WR, Liao HI, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. PNAS 2009; 107: 5551-5556.
30. Johansson M, Brismar S, Karisson A. Human deoxycytidine kinase is located in the cell nucleus. PNAS 1997; 94: 11941-11945.
31. Sabini E, Hazra S, Konrad M, Burley SK. Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine. Nucleic Acids Res 2007; 35:186-192.
32. Grove KL, Guo X, Liu SH, Goa Z, Chu CK, Cheng YC. Anti cancer activity of beta-l-dioxolane-cytidine, a novel nucleoside analogs with the unnatural L configuration. Cancer Res 1995; 55, 3008-3011.
33. Chang CN, Skalski V, Zhou LH, Cheng YC. Biochemical pharmacology of (+) - and (-)-2', 3' -dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 22414-22420.
34. Verri A, Focher F, Priori G, et al. Lack of enantiospeificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol 1997; 51:132-138.
35. Saul FA, Vulliez-le Normand B, Lema F, Bentley GA. Crystal structure of a dominant B-cell Epitope from the preS2 Region of Hepatitis B Virus in the Form of an Inserted Peptide Segment in Maltodextrin-binding Protein. J Mol Biol 1998; 280: 185-192.
36. Belon CA, Frick DN. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol 2009; 4: 277-293.
37. Tai CL, Chi WK, Chen DS, Hwang LH. The Helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Viro 1996; 70: 8477-8484.
38. Chene P. NS3 Helicases as Drug Targets. Curr Chem Biol 2009; 3: 334-342.
39. Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis C Virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insight into the mode of unwinding. Structure 1998; 15: 89-100.
40. Yao NH, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional proteasehelicase. Structure with folding and design 1999; 15: 1353-1363.
41. Chen CS, Chiou CT, Chen GS, et al. Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase. J Med Chem 2009; 52, 2716-2723.
42. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal Structure of the Catalytic Domain of HIV-1 Integrase: Similarity to Other Polynucleotidyl Transferases. Science 1994; 266: 1981-1986.
43. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 Protease: A major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27: 249-284.
44. Erbel P, Schiering N, Arcy AD, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006; 13: 372-373.
45. Yeo H, Li Y, Fu L, Zhu JL, et al. Synthesis and Antiviral Activity of Helioxanthin Analogues, J Med Chem 2005; 48, 534-546.
46. Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L. Helicase inhibition by anthracyclin anticancer agents. Mol Pharmacol 1992; 41: 993-999.
47. Smith RM, Wu GY. Structure based design of hepatitis C virus inhibitors. J Viral Hepat 2003; 10: 405-412.
48. Manfroni G, Paeshuyse J, Massari S, et al. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. J Med Chem 2009; 52: 3354-3365.
49. Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (Acadirachta indica). Curr Sci 2002; 82: 1336-1345.
50. Jones PS, Ley SV, Morgan ED, Santafianos D. The Chemistry of the Neem Tree; Martin Jacobson, Ed. CRC Press: Boca Raton 1988; 1: pp. 19-42.
51. Maity P, Hansda D, Bandyopadhyay U, Mishra DK. Biological activities of crude extracts and chemical constituents of Bael, Aegle marmelos. Indian J Exp Biol 2009; 47: 849-869.
52. Nayak A, Mandal S, Banerji A, Banerji J. Review on chemistry and pharmacology of Murraya koenigii Spreng (Rutaceae). J Chem Pharm Res 2010; 2: 286-299.
53. Rameshkumar G, Ravichandran S, Kaliyavarathan G, Ajithkumar TT. Antimicrobial Peptide from the Crab, Thalamita crenata (Latreille, 1829). World J Fish & Marine Sci 2009; 1: 74-79.
54. Sampath Kumar NS, Nazeer RA, Jaiganesh R. Purification and biochemical characterization of antioxidant peptide from horse mackerel (Magalaspis cordyla) viscera protein. Peptides 2011; 32: 1496-1501.
55. Li YF, Wang GF, He PL, et al. Synthesis of Anti-Hepatitis B Virus activity of novel benzimidazole derivatives. J Med Chem 2006; 49, 4790-4794.
56. Li YF, Wang GF, Huang WG, et al. Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as new class of inhibitors of hepatitis B virus. Eur J Med Chem 2007; 42:1358-1364.
57. Chandra V, Jasti J, Kaur P, et al. Crystal structure of a complex formed between a snake venom phospholipase A(2) and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 A resolution. J Biol Chem 2002; 277: 41079-41085.
58. Chandra V, Jasti J, Kaur P, et al. Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr D Biol Crystallogr 2002; 58: 1813-1819.
59. Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011.
60. Gozdek A, Zhukov I, Polkowska A, et al. NS3 peptide, a novel potent Hepatitis C Virus NS3 Helicase Inhibitor: Its Mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother 2008; 52: 393-301.
61. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors. VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-17514.
62. Luo D, Wei N, Doan DN, et al. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem 2010; 285: 18817-18827.
63. Sampath A, Xu T, Chao A, Luo D, Lescar J, Vasudevan SG. Structure-Based Mutational Analysis of the NS3 Helicase from Dengue virus. J Virol 2006; 80: 6686-6690.
64. Matusan AE, Pryor MJ, Davidson AD, Wright PJ. Mutagenesis of the Dengue Virus Type 2 NS3 protein within and outside Helicase Motifs: Effects on Enzymatic Activity and Virus Replication. J Virol 2001; 75: 9633-9643.
65. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanabhan. Association between NS3 and NS5 Proteins of Dengue Virus Type 2 in the Putative RNA Replicase Is Linked to Differential Phosphorylation of NS5. J Biol Chem 1995; 270: 19100-19106.